If zolbetuximab was not given in first line in metastatic gastric cancer with CLDN 18.2, would you give it with second line ?

The short answer is no. Available data in later lines have shown essentially no single-agent activity (Klempner et al., PMID 37490286). Because zolbetuximab is a chimeric (mouse/human) IgG1 naked antibody that relies entirely on immune effector mechanisms (ADCC and CDC) to kill tumor cells, it does ...

There is no correct answer to this question, as, to the best of my knowledge, zolbetuximab has not been combined with any other regimen than a first-line fluoropyrimidine/platinum regimen.

As a single agent, the drug has modest activity (objective response rate of ORR of 9% in patients whose tumor wa...